Long-acting β2-agonists in adult asthma and the pattern of risk of death and severe asthma outcomes: A study using the GPRD

European Respiratory Journal

Volumn 36, Issue 3, 2010, Pages 494-502

  De Vries, F ^a,b   Setakis, E ^a   Zhang, B ^a   Van Staa, T P ^a,b  

^a MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY   (United Kingdom)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

2 agonists; Asthma; Asthma death; Inhaled corticosteroids

Indexed keywords

BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CICLESONIDE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; FLUTICASONE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LONG ACTING DRUG; MOMETASONE FUROATE; SHORT ACTING DRUG; XANTHINE DERIVATIVE;

ADULT; ADULT DISEASE; ARTICLE; ASTHMA; CORTICOSTEROID THERAPY; DATA BASE; DISEASE SEVERITY; DRUG EXPOSURE; DRUG MEGADOSE; FEMALE; FOLLOW UP; GENERAL PRACTICE; HOSPITALIZATION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; TREATMENT OUTCOME; TREND STUDY; UNITED KINGDOM;

ADRENAL CORTEX HORMONES; ADRENERGIC BETA-2 RECEPTOR ANTAGONISTS; ADULT; ANTI-ASTHMATIC AGENTS; ASTHMA; FEMALE; GREAT BRITAIN; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RISK; TREATMENT OUTCOME;

EID: 77956607782     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00124209     Document Type: Article

References (36)

1. Salpeter SR, Buckley NS, Ormiston TM, et al. Meta-analysis: effect of long-acting β-agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med 2006; 144: 904-912.
2. Ernst P, McIvor A, Ducharme FM, et al. Safety and effectiveness of long-acting inhaled β-agonist bronchodilators when taken with inhaled corticosteroids. Ann Intern Med 2006; 145: 692-694. (Pubitemid 46768845)
3. 2-agonists versus placebo in addition to inhaled corticosteroids in children and adults with chronic asthma. Cochrane Database Syst Rev 2005; 19: CD005535.
4. 2-agonists and inhaled steroids versus higher dose of inhaled steroids in children and adults with persistent asthma. Cochrane Database Syst Rev 2005; 19: CD005533.
5. 2- agonists for chronic asthma in adults and children where background therapy contains varied or no inhaled corticosteroid. Cochrane Database Syst Rev 2007; 24: CD001385.
6. Sturdy PM, Victor CR, Anderson HR, et al. Psychological, social and health behaviour risk factors for deaths certified as asthma: a national case-control study. Thorax 2002; 57: 1034-1039.
7. Sturdy PM, Butland BK, Anderson HR, et al. Deaths certified as asthma and use of medical services: a national case-control study. Thorax 2005; 60: 909-915.
8. Rabe KF, Vermeire PA, Soriano JB, et al. Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study. Eur Respir J 2000; 16: 802-807.
9. Partridge MR, van der Molen T, Myrseth SE, et al. Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study. BMC Pulm Med 2006; 6: 13.
10. Williams LK, Pladevall M, Xi H, et al. Relationship between adherence to inhaled corticosteroids and poor outcomes among adults with asthma. J Allergy Clin Immunol 2004; 114: 1288-1293. (Pubitemid 39575880)
11. Apter AJ, Reisine ST, Affleck G, et al. Adherence with twice-daily dosing of inhaled steroids. Socioeconomic and health-belief differences. Am J Respir Crit Car Med 1998; 157: 1810-1817. (Pubitemid 28311263)
12. British Thoracic Society, Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma. www. brit-thoracic.org.uk/ Portals/0/Clinical%20Information/Asthma/Guidelines/asthmaupdatenov05.pdf Date last accessed: July 1, 2008. Date last updated: November 2005.
13. Parkinson J, Davis S, van Staa TP. The General Practice Research (GPRD) Database: now and the future. In: Pharmacovigilance. R Mann, ed. Chichester, John Wiley & Sons, 2007; pp. 341-348.
14. British Thoracic Society, British Paediatric Association, Royal College of Physicians, et al, Guidelines on the management of asthma. Thorax 1993; 48: S1-S24.
15. Soriano JB, Maier WC, Visick G, et al. Validation of general practitioner-diagnosed COPD in the UK General Practice Research Database. Eur J Epidemiol 2001; 17: 1075-1080.
16. Shah AD, Martinez C. A comparison of the cause of death recorded in the General Practice Research Database with national mortality statistics in England and Wales. Pharmacoepid Drug Saf 2004; 13: S2-S3.
17. Smith BP, Vandenhende FR, DeSante KA, et al. Confidence interval criteria for assessment of dose prportionality. Pharmaceutical Research 2000; 17: 1278-1283.
18. Zhang B, de Vries F, Setakis E, et al. The pattern of risk of myocardial infarction in patients taking asthma medication: a study with the General Practice Research Database. J Hypert 2009; 27: 1485-1492.
19. Sears MR, Ottosson A, Radner F, et al. Long-acting β-agonists: a review of formoterol safety data from asthma clinical trials. Eur Respir J 2009; 33: 21-32.
20. Nelson HS, Weiss ST, Bleecker ER, et al. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006; 129: 15-26.
21. Bateman E, Nelson H, Bousquet J, et al. Meta-analysis: effects of adding salmeterol to inhaled corticosteroids on serious asthmarelated events. Ann Intern Med 2008; 149: 33-42.
22. Crane J, Pearce N, Flatt A, et al. Prescribed fenoterol and death from asthma in New Zealand, 1981-83: case-control study. Lancet 1989; 1: 917-922.
23. Pearce N, Grainger J, Atkinson M, et al. Case-control study of prescribed fenoterol and death from asthma in New Zealand, 1977-81. Thorax 1990; 45: 170-175.
24. Grainger J, Woodman K, Pearce N, et al. Prescribed fenoterol and death from asthma in New Zealand, 1981-7: a further case-control study. Thorax 1991; 46: 105-111.
25. Woodman K, Pearce N, Beasley R, et al. Albuterol and deaths from asthma in New Zealand from 1969 to 1976: a case-control study. Clin Pharmacol Ther 1992; 51: 566-571.
26. Spitzer WO, Suissa S, Ernst P, et al. The use of b-agonists and the risk of death and near death from asthma. N Engl J Med 1992; 326: 501-506.
27. Ernst P, Spitzer WO, Suissa S, et al. Risk of fatal and near-fatal asthma in relation to inhaled corticosteroid use. JAMA 1992; 268: 3462-3464.
28. Castle W, Fuller R, Hall J, et al. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ 1993; 306: 1034-1037. (Pubitemid 23105961)
29. Suissa S, Ernst P, Boivin JF, et al. A cohort analysis of excess mortality in asthma and the use of inhaled β-agonists. Am J Respir Crit Care Med 1994; 149: 604-610. (Pubitemid 24082213)
30. Meier CR, Jick H. Drug use and pulmonary death rates in increasingly symptomatic asthma patients in the UK. Thorax 1997; 52: 612-617.
31. Guite HF, Dundas R, Burney PG. Risk factors for death from asthma, chronic obstructive pulmonary disease, and cardiovascular disease after a hospital admission for asthma. Thorax 1999; 54: 301-307.
32. Suissa S, Ernst P, Benayoun S, et al. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med 2000; 343: 332-336.
33. Martin RM, Shakir S. Age- and gender-specific asthma death rates in patients taking long-acting b2-agonists: prescription event monitoring pharmacosurveillance studies. Drug Saf 2001; 24: 475-481.
34. Lanes SF, García Rodríguez LA, Huerta C. Respiratory medications and risk of asthma death. Thorax 2002; 57: 683-686.
35. Anderson HR, Ayres JG, Sturdy PM, et al. Bronchodilator treatment and deaths from asthma: case-control study. BMJ 2005; 330: 11-77.
36. Williams C, Crossland L, Finnerty J, et al. Case-control study of salmeterol and near-fatal attacks of asthma. Thorax 1998; 53: 7-13.